India Stock Spotlight: BEL, Sun Pharma & More Analyzed

Indian equity markets entered March 2026 carrying the weight of three consecutive months of foreign institutional investor outflows, a rupee under pressure near 84.5 against the dollar, and a Nifty 50 that has shed roughly 8% from its September 2025 peak according to NSE data. Against that backdrop, certain stocks are being watched very closely — not because the macro is favorable, but because their individual earnings trajectories may be strong enough to decouple from the index. Bharat Electronics, Sun Pharma, Thermax, and Natco Pharma sit at the center of that debate right now.

The Core Problem

The central tension in Indian markets in early 2026 is a familiar one: strong domestic earnings narratives colliding with deteriorating global risk appetite. FII net outflows from Indian equities reached approximately ₹1.5 lakh crore ($18 billion) between October 2025 and February 2026, according to NSDL data — one of the heaviest sustained selling periods since the 2022 global rate-shock cycle. That selling pressure has been largely indiscriminate, pulling down quality names alongside weaker ones.

Bharat Electronics Limited (BEL) trades in the defense electronics space — a sector receiving direct budget support, with India's Union Budget 2025-26 allocating ₹6.81 lakh crore to defense, representing a 4.79% increase over the prior year according to Ministry of Finance documents. BEL's order book stood at approximately ₹76,000 crore as of Q3 FY26, providing multi-year revenue visibility that most Indian industrials cannot match.

Sun Pharmaceutical, India's largest pharma company by market cap, faces a different set of variables. Its specialty segment — which now contributes roughly 18% of U.S. revenue according to the company's Q3 FY26 investor presentation — carries higher margins but also higher regulatory risk from the U.S. FDA. Thermax, an energy and environment engineering company, is exposed to India's capex cycle, which showed signs of softening in Q3 FY26 as government spending front-loading gave way to election-related fiscal conservatism. Natco Pharma, a mid-cap generic pharmaceutical play, remains driven by U.S. generic drug approvals and para-IV filings. The question isn't whether these are good companies. The question is whether their valuations already price in the good news — and none of the bad.

Historical Parallel

The current episode in Indian markets bears resemblance to the mid-2018 correction, triggered by the IL&FS default crisis in September 2018 and compounded by sustained FII selling driven by a rising U.S. dollar and emerging market contagion. Between August and October 2018, the Nifty Midcap 100 index fell approximately 20% while the broader Nifty 50 dropped around 12%, according to NSE historical data. Crucially, that correction was also sector-selective in its eventual recovery.

Defense and pharma names recovered faster than the broader market in 2019, once domestic institutional investors — particularly mutual funds — stepped in to absorb the FII selling pressure. DIIs purchased a net ₹68,000 crore in Indian equities in the second half of 2018 alone, per SEBI data, providing a floor that prevented a deeper crash.

The lesson from 2018 is twofold. First, companies with government-linked order books — like BEL and HAL — tend to be more insulated during periods of macro uncertainty because their revenue visibility doesn't depend on private sector confidence cycles. Second, pharma exporters with U.S. revenue streams can act as natural rupee depreciation hedges: a weaker rupee translates directly into higher reported revenues in rupee terms for companies earning in dollars.

But 2018 also reminded investors that even quality names can underperform for 12-18 months if the macro headwind is strong enough. Timing matters — and the macro hasn't turned yet.

The Data Under the Hood

Break down the financials and the divergence across these four names becomes sharper.

Bharat Electronics reported revenue of approximately ₹6,900 crore in Q3 FY26, a 14.2% year-on-year increase, with EBITDA margins expanding to 25.3% — among the highest in the Indian defense manufacturing space, according to the company's quarterly earnings release. Its price-to-earnings ratio of approximately 42x trailing earnings reflects a premium that the market has historically been willing to pay for defense order book visibility, but it also leaves limited margin of safety if order inflows disappoint.

Sun Pharma's Q3 FY26 consolidated revenue came in at ₹13,240 crore, up 10.1% year-on-year, with net profit of ₹2,810 crore, a 13.4% increase, according to company filings. Its U.S. business — historically the primary earnings driver — grew 8% in dollar terms. The specialty pipeline, including dermatology brands like Ilumya and Cequa, now contributes disproportionately to U.S. profitability given their 60-70% gross margins versus 30-40% for generics.

Thermax presents a more complex picture. Order inflows for the nine months ended December 2025 stood at approximately ₹8,200 crore — flat year-on-year — as private sector capex decisions slowed, according to Thermax's investor communications. Revenue grew 11% but margin pressure from input cost inflation kept EBITDA margins at 11.2%, below the 12-13% the company has historically delivered in strong capex cycles.

Natco Pharma, the smallest of the four by market cap at approximately ₹15,000 crore, reported Q3 FY26 net profit of ₹310 crore — a 28% year-on-year jump driven by U.S. generic launches including its gRevlimid (lenalidomide) exclusivity window, per company disclosures. That exclusivity ends in mid-2026, creating a significant earnings cliff that the market is attempting to price in real time. Natco's forward P/E of approximately 18x assumes smooth transition to the next product cycle. That assumption deserves scrutiny.

Two Sides of the Coin

The bull case for this basket of stocks centers on India's structural growth story remaining intact beneath the cyclical noise.

Defense spending in India is non-discretionary and growing. The government's push for domestic defense procurement — with a 75% indigenization target for defense capital procurement by FY27 according to Ministry of Defense policy documents — structurally advantages BEL, which derives over 90% of its revenue from domestic government orders. Even in a risk-off environment, government order flows continue. That predictability commands a premium.

For Sun Pharma, the specialty transition represents a genuine business model upgrade. Specialty drugs carry significantly higher barriers to generic competition and longer revenue durability. If the U.S. specialty segment grows to 25% of U.S. revenue by FY28 — a trajectory that current launch cadence supports — margin expansion could be substantial.

The bear case is harder to dismiss. Thermax's flat order intake signals that India's private capex cycle — which drove industrial earnings outperformance between 2022 and 2024 — may be cooling faster than consensus expects. If private investment growth slows from the 8-9% pace seen in FY25 to 4-5% in FY26, as some early indicators suggest, companies like Thermax face multiple compression alongside earnings pressure.

Natco's gRevlimid cliff is the most acute near-term risk in the group. Generic lenalidomide generated estimated revenues of ₹900-1,000 crore annually during its exclusivity window — a figure that largely disappears once the market opens to broader generic competition. No single pipeline asset currently in Phase III or awaiting ANDA approval appears capable of replacing that contribution by FY27. The stock's current pricing may be too optimistic.

Scenarios & What-Ifs

Scenario One — Domestic Demand Holds, FII Outflows Stabilize (probability: moderate). If the U.S. Federal Reserve signals a more accommodative stance in its March-April 2026 meetings — reducing the dollar strength that has been pressuring emerging market currencies — FII outflows from India could reverse. In that environment, high-quality names like BEL and Sun Pharma would likely see rapid re-rating, with BEL potentially testing the ₹320-340 range and Sun Pharma retesting its 52-week highs near ₹1,900.

Scenario Two — Rupee Depreciation Persists, Selective Outperformance (probability: moderate to high). Dollar strength continues through mid-2026. Rupee weakens toward 86-87 levels. In this scenario, rupee earners like Thermax underperform while dollar earners — Sun Pharma and Natco — benefit from translation gains. The bifurcation within this stock group widens rather than narrows.

Scenario Three — Global Risk-Off Accelerates (probability: lower but real). A global credit event or significant geopolitical escalation triggers broad emerging market selling. All four names sell off regardless of fundamentals, potentially offering entry points at valuations last seen in late 2023. Patience would be the only portfolio tool that works in that scenario.

The Bottom Line

BEL and Sun Pharma have the clearest fundamental anchors in this group — government order books and a pharma specialty transition don't disappear because FIIs are selling. Thermax needs private capex to re-accelerate before its story gets interesting again, and Natco has a real earnings cliff coming in mid-2026 that the current price may not fully respect. The macro is messy, but the stock-specific differences here are sharp enough to matter.